5 results match your criteria: "Ghent University and VIB Center for Inflammation Research[Affiliation]"
Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial.
Semin Arthritis Rheum
December 2024
Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany.
Objective: To test trial and longitudinal known group discrimination of thresholds of meaning for improvement and health states of the ASAS Health Index (ASAS HI) in patients with active axSpA treated in a randomized study.
Methods: Data from baseline and week 48 from the tight-controlled, treat-to-target trial TICOSPA study were used. The performance of different thresholds to assess change or health states of the ASAS HI were evaluated between arms and against changes in patients' relevant outcomes and various external responder criteria.
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.
RMD Open
August 2024
Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium.
Article Synopsis
- This study looked at how well a drug called certolizumab pegol (CZP) works for people with a condition called axial spondyloarthritis (axSpA) over 12 weeks.
- It found that while most patients showed strong improvements in inflammation measured by tests like blood tests and MRI scans, fewer than half showed similar improvements in their symptoms or daily activities.
- The results suggest that looking at inflammation alone might not give the full picture of how the treatment is working for patients with axSpA.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Ann Rheum Dis
April 2023
Affiliated to Second Military Medical University, Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Shanghai, China.
Article Synopsis
- Axial spondyloarthritis (axSpA) is a complex condition that requires new treatments, prompting two phase 3 trials (BE MOBILE 1 and BE MOBILE 2) to assess the effectiveness and safety of bimekizumab, a new drug targeting two interleukins (IL-17A and IL-17F).
- In these 52-week trials, patients with active nr-axSpA and r-axSpA were randomized to receive either bimekizumab or a placebo, with significant improvements observed at 16 weeks in the primary endpoint (ASAS40) and other measures of disease activity and inflammation.
- While bimekizumab showed positive effects, it was
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*.
Angew Chem Int Ed Engl
April 2021
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Article Synopsis
- Scientists are racing to develop vaccines against SARS-CoV-2 to reduce severe illness and death from COVID-19.
- The study introduces an innovative adjuvant, IMDQ-PEG-CHOL, which enhances immune response and targets lymph nodes effectively while minimizing systemic inflammation.
- Testing showed that this adjuvant significantly improved antibody production and neutralizing capabilities against the virus in mouse models, demonstrating its potential for use in COVID-19 vaccines.
Cellular diversity in the colon: another brick in the wall.
Nat Rev Gastroenterol Hepatol
July 2019
Department of Gastroenterology, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium.